TY - JOUR
T1 - Gender differences in cancer patients with acute venous thromboembolism
AU - Martin-Martos, Francisco
AU - Trujillo-Santos, Javier
AU - Barron, Manuel
AU - Vela, Jeronimo
AU - Javier Marchena, Pablo
AU - Braester, Andrei
AU - Hij, Adrian
AU - Hernandez-Blasco, Luis
AU - Verhamme, Peter
AU - Manuel, Monreal
N1 - Publisher Copyright:
© 2015 Elsevier Ltd. All rights reserved.
PY - 2015/2/1
Y1 - 2015/2/1
N2 - Background: The outcome of cancer patients with acute venous thromboembolism (VTE) may differ according to gender. Methods: We used the RIETE database to compare the rate of VTE (pulmonary embolism [PE] or deep vein thrombosis [DVT]) recurrences), major bleeding and mortality during the course of anticoagulation, according to gender. Results: As of August 2014, 11,055 patients with active cancer were enrolled in RIETE, of whom 5,104 (46%) were women. During the course of anticoagulation (mean: 142 days), 505 patients developed recurrent VTE, 429 bled and 2730 died. Compared with men, women had a significantly lower rate of fatal bleeding (risk ratio [RR]: 0.69; 95% CI: 0.47-0.99) and death (RR: 0.90; 95% CI: 0.83-0.97), and a non-significantly lower rate of PE recurrences (RR 0.83; 95% CI: 0.65-1.06) and major bleeding (RR: 0.89; 95% CI: 0.74-1.08). Conclusions: During the course of anticoagulation, cancer women with VTE had a better outcome than men.
AB - Background: The outcome of cancer patients with acute venous thromboembolism (VTE) may differ according to gender. Methods: We used the RIETE database to compare the rate of VTE (pulmonary embolism [PE] or deep vein thrombosis [DVT]) recurrences), major bleeding and mortality during the course of anticoagulation, according to gender. Results: As of August 2014, 11,055 patients with active cancer were enrolled in RIETE, of whom 5,104 (46%) were women. During the course of anticoagulation (mean: 142 days), 505 patients developed recurrent VTE, 429 bled and 2730 died. Compared with men, women had a significantly lower rate of fatal bleeding (risk ratio [RR]: 0.69; 95% CI: 0.47-0.99) and death (RR: 0.90; 95% CI: 0.83-0.97), and a non-significantly lower rate of PE recurrences (RR 0.83; 95% CI: 0.65-1.06) and major bleeding (RR: 0.89; 95% CI: 0.74-1.08). Conclusions: During the course of anticoagulation, cancer women with VTE had a better outcome than men.
KW - Anticoagulant drugs
KW - Cancer
KW - Gender
KW - Hemorrhage
KW - Mortality
KW - Recurrence
KW - Venous thromboembolism
UR - http://www.scopus.com/inward/record.url?scp=84923035170&partnerID=8YFLogxK
U2 - 10.1016/s0049-3848(15)50433-7
DO - 10.1016/s0049-3848(15)50433-7
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 25903526
AN - SCOPUS:84923035170
SN - 0049-3848
VL - 135
SP - S12-S15
JO - Thrombosis Research
JF - Thrombosis Research
IS - S1
ER -
